Health Boards
Thu-16-10-2014, 07:40 AM
Recently a "new" medication was released in the Netherlands for treating Multiple Slerose. It is based on the working substance Dimethylfumarate.
The medication draws attention because of its price, and was in a Television transmission compared to a much cheaper medication in reality one of our well known psoriasis medications.
The neurologist that brought this discrepancy to the attention of the public, dr. Bob van Oosten, says in this transmission, that for MS he is only allowed by the protocol to prescribe this new medication to MS patients. (Long live the protocol designed by [old|wise] men).
In the mean time, the minister of Health, mrs. Schippers, is also attached to the case, and she already signaled to the producing pharmacologist that they are way too expensive, which has also been mentioned in an article in the papers.
Unfortunately she at the same time says that it should be dealt with by the European Parliament, which shifts this item to somewhere in the future. The EU does not have the name to be quick on items that are really important for the civilian.
Pharma says that the price is relevant and in balance with all the research that has been done, but:
- Why is the other medication than so much cheaper? And this has 20 years of field experience.
- And where are those studies?
If you are interested you can watch the transmission at [web]https://www.rtlxl.nl/#!/132237/ce0a02c6-7153-3bba-b11e-c259ef1b9a46[/web]. It is in dutch, but I think it is not so complicated that you would not be able to follow it.
It is on a site called "Transmission missed?", where one can review all kinds of news transmissions.
The item on the medication starts at around 12:45 minutes, you are able to skip to this time.
The medication draws attention because of its price, and was in a Television transmission compared to a much cheaper medication in reality one of our well known psoriasis medications.
The neurologist that brought this discrepancy to the attention of the public, dr. Bob van Oosten, says in this transmission, that for MS he is only allowed by the protocol to prescribe this new medication to MS patients. (Long live the protocol designed by [old|wise] men).
In the mean time, the minister of Health, mrs. Schippers, is also attached to the case, and she already signaled to the producing pharmacologist that they are way too expensive, which has also been mentioned in an article in the papers.
Unfortunately she at the same time says that it should be dealt with by the European Parliament, which shifts this item to somewhere in the future. The EU does not have the name to be quick on items that are really important for the civilian.
Pharma says that the price is relevant and in balance with all the research that has been done, but:
- Why is the other medication than so much cheaper? And this has 20 years of field experience.
- And where are those studies?
If you are interested you can watch the transmission at [web]https://www.rtlxl.nl/#!/132237/ce0a02c6-7153-3bba-b11e-c259ef1b9a46[/web]. It is in dutch, but I think it is not so complicated that you would not be able to follow it.
It is on a site called "Transmission missed?", where one can review all kinds of news transmissions.
The item on the medication starts at around 12:45 minutes, you are able to skip to this time.
